Avalo Therapeutics, Inc. (AVTX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Avalo Therapeutics, Inc. reported revenue of $59.0K, down 86.6% from the prior year. The company ran a net loss, with a net margin of -132642.4%. It held $116.46M in total assets against $33.41M in total liabilities.
Key ratios (FY2025)
-123601.7%
Operating margin
-132642.4%
Net margin
-94.2%
Return on equity
-86.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59.0K | $441.0K | $1.92M | $18.05M | $5.40M | $6.70M | $6.75M | $7.03M | $27.81M | — |
| Cost of Revenue | — | — | $1.28M | $3.43M | $1.49M | $300.0K | -$566.5K | $3.26M | $635.6K | — |
| Operating Income | -$72.92M | -$68.51M | -$27.35M | -$37.44M | -$82.13M | -$72.84M | -$16.14M | -$35.38M | $13.89M | -$16.08M |
| Net Income | -$78.26M | -$35.13M | -$31.54M | -$41.66M | -$84.38M | -$63.50M | -$16.07M | -$40.05M | $11.87M | -$16.47M |
| EPS (Diluted) | $-5.84 | $-20.91 | $-113.58 | $-1063.00 | — | — | — | $-1.20 | $0.42 | $-1.87 |
| Total Assets | $116.46M | $150.73M | $20.99M | $33.37M | $80.21M | $43.76M | $36.11M | $70.25M | $42.81M | $5.77M |
| Total Liabilities | $33.41M | $17.70M | $13.69M | $44.28M | $57.13M | $19.19M | $15.11M | $49.34M | $14.95M | $5.56M |
| Shareholders' Equity | $83.05M | $133.03M | $7.30M | -$10.91M | $23.08M | $24.56M | $21.00M | $20.91M | $27.86M | $207.0K |
| Cash & Equivalents | $15.86M | $134.55M | $7.42M | $13.17M | $54.59M | $18.92M | $3.61M | $10.65M | $2.47M | $5.13M |
| Operating Cash Flow | -$51.46M | -$49.06M | -$30.68M | -$26.75M | -$70.89M | -$40.54M | -$19.13M | -$3.13M | $12.58M | -$14.57M |
| Capital Expenditures | — | — | — | $95.0K | $113.0K | $63.0K | $262.0K | $564.4K | $23.3K | $34.9K |
| Shares Outstanding | 18.51M | 10.47M | 801.7K | 39.3K | 9.40M | 75.00M | 44.38M | 40.80M | 31.27M | 9.43M |